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Abstract
Background. Osteoprotegerin (OPG) is a marker and reg-
ulator of arterial calcification, and it is related to car-
diovascular survival in haemodialysis patients. The link
between OPG and aortic stiffening—a consequence of ar-
terial calcification—has not been previously evaluated in
this population, and it is not known whether OPG-related
mortality risk is mediated by arterial stiffening.
Methods. At baseline, OPG and aortic pulse wave velocity
(PWV) were measured in 98 chronic haemodialysis patients
who were followed for a median of 24 months. The relation-
ship between OPG and PWV was assessed by multivariate
linear regression. The role of PWV in mediating OPG re-
lated cardiovascular mortality was evaluated by including
both OPG and PWV in the same survival model.
Results. At baseline mean (standard deviation) PWV was
11.2 (3.3) m/s and median OPG (interquartile range) was
11.1 (7.5–15.9) pmol/L. There was a strong, positive, linear
relationship between PWV and lnOPG (P = 0.009, model
R2 = 0.540) independent of covariates. During follow-up
23 patients died of cardiovascular causes. In separate uni-
variate survival models both PWV and lnOPG were related
to cardiovascular mortality [hazard ratios 1.31 (1.14–1.50)
and 8.96 (3.07–26.16), respectively]. When both PWV and
lnOPG were entered into the same model, only lnOPG re-
mained significantly associated with cardiovascular mor-
tality [hazard ratio 1.11 (0.93–1.33) and 7.18 (1.89–27.25),
respectively).
Conclusion. In haemodialysis patients OPG is strongly re-
lated to PWV and OPG related cardiovascular mortality
risk is, in part, mediated by increased PWV.
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Introduction
A number of cross-sectional studies reported high preva-
lence of vascular calcification in haemodialysis (HD) pa-
tients [1–4]. In addition, prospective studies demonstrated
that vascular calcification of the intima and media of the
large arteries is associated with increased risk of cardiovas-
cular events and mortality in this population, independent
of classical risk factors [5].
Stiffening of the wall of the aorta—as assessed for exam-
ple by carotid-femoralis pulse wave velocity (PWV)—has
emerged as a robust and independent predictor of all cause
and cardiovascular mortality in HD patients [6,7]. Aortic
stiffening leads to decreased cushioning function, faster
pulse wave propagation and earlier return of the reflected
wave to the heart resulting in increased central pulse pres-
sure, increased systolic pressure load to the heart and de-
creased diastolic pressure to boost coronary circulation
[8,9]. The positive relationship between the extent of aortic
calcification and PWV [10] provides a pathway that is—at
least in part—plausible to explain for the cardiovascular
morbid events seen in HD patients with arterial calcifica-
tions.
Recent studies have indicated that osteoprotegerin
(OPG), a soluble decoy receptor of the osteoclast activator
RANKL, acts as an important regulatory molecule in vas-
cular disease, such as arterial calcification and atheroscle-
rosis [11,12]. Moreover, elevated OPG levels have been
associated with the progression of vascular calcification
in patients receiving long-term haemodialysis [13], and a
recent analysis showed that OPG levels can, in part, ex-
plain for the association between coronary artery calcifica-
tion and chronic kidney disease [14]. OPG is also a novel
marker of cardiovascular mortality and clinical events in
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patients with acute myocardial infarction complicated with
heart failure [15]. The link between serum OPG levels and
cardiovascular survival in HD [16] and renal transplant pa-
tients [17] further strengthens the role of OPG as a clinically
useful prognostic marker among these patients. While the
relationship between OPG and arterial calcification may
provide the broad framework to explain for its effects on
survival, downstream elements of a possible causal rela-
tionship are yet to be identified.
We hypothesize that increased serum OPG levels in HD
patients indicate arterial calcification that leads to increased
PWV with consequent cardiovascular events. To test this we
analysed the relationship between OPG levels and PWV in
patients on maintenance HD. Furthermore, we investigated
the inter-relationship of PWV and serum OPG levels on




This was a prospective cohort study among 98 chronic
HD patients with baseline cross-sectional analysis of the
relationship between PWV and OPG levels, and survival
analysis for cardiovascular mortality using PWV and OPG
as predictor variables during follow-up.
All chronic (>3 months on HD) patients of two dialysis
units of a dialysis network were invited to participate. No
specific exclusion criteria were applied. Patients who gave
written informed consent for participation were included
and had baseline clinical assessment, laboratory and PWV
measurements and then followed for a median (range) of
24 (0–31) months. Baseline demographic and clinical data
were gathered by chart review, and laboratory parameters
were measured prior to a midweek dialysis at the time of
arterial stiffness assessment. Overt cardiovascular disease
was considered to be present if the patient had a docu-
mented history of myocardial infarction, revascularization
procedure, stroke or peripheral artery disease. Heart failure
was not included in the definition of cardiovascular dis-
ease as this frequently would have been based on physician
assessment only, and signs of hypervolaemia in these HD
patients could have led to misclassification of heart failure.
The protocol was approved by the Ethics Committee of
the dialysis network and all patients gave written informed
consent to their participation.
PWV recordings
Arterial stiffness was measured as carotid-femoral PWV
and carotid augmentation index (AI) using the validated
PulsePen tonometer (DiaTecne, Milan, Italy) before a mid-
week HD session with the patient in the supine position
[18]. In each subject two sequences of measurements were
performed, and their mean was used for statistical analysis.
The PulsePen device measures the time difference be-
tween the R wave of the ECG and the foot of the pulse
pressure wave—obtained sequentially above the carotid and
the femoral arteries using a handheld tonometer—to calcu-
late pulse transit time between these two sites. The average
signal of at least 10 heart cycles was used in the measure-
ments at both sites for the assessment of PWV. Surface
tape measurement of the distance between the carotid and
femoral measurement sites was used to calculate PWV by
the PulsePen software. To ensure that alterations in blood
pressure and heart rate would not bias the results of PWV
assessment, the software of PulsePen automatically rejected
measurements in which blood pressure or heart rate changed
>5% during the time between the sequential carotid and
femoral pulse wave recordings.
Carotid tonometric measurements were performed on the
side contralateral to the fistula or tunnelled jugular line. The
same sides were used to obtain femoral pressure waves. All
femoral and carotid pulse pressure wave recordings were
evaluated for quality by a single observer (TEHO). Previ-
ously we evaluated the intra- and interobserver variability
of PWV measurements obtained by the PulsePen device
in haemodialysis patients and these were 4.8 and 7.3%,
respectively.
Blood pressure and heart rate were recorded by the val-
idated BpTru device (VSM Medtech, Vancouver, Canada)
with two sequential measurements manually averaged.
Laboratory measurements
After the arterial stiffness measurements and prior to
dialysis, blood samples were collected for laboratory mea-
surements. Serum OPG levels were measured by ELISA us-
ing the commercially available kit by Immundiagnostic AG
Bensheim, Germany. Intra- and inter-assay coefficients of
variation (CV) were below 8% and 10% with a lower detec-
tion limit of 0.14 pmol/L. Other parameters were measured
by standard laboratory procedures.
Statistical analysis
To assess baseline association between PWV and OPG lin-
ear regression analysis was used. First, we performed uni-
variate analysis using PWV as the outcome and OPG as the
predictor variable. The variables considered were the ones
listed in Table 1, with the exception of the carotid augmen-
tation index. Next, a multivariate model was constructed
that included all other variables besides OPG that showed
a significant association with PWV in separate univariate
models.
To evaluate the inter-relationship of PWV and OPG
levels on cardiovascular mortality Cox proportional hazard
regression analyses were used. Cardiovascular mortality
was defined as sudden cardiac death, death related to
myocardial infarction, arrhythmia, heart failure or stroke
as assessed by the attending physician. Follow-up was
censored at the time of death from other causes, transplan-
tation, transfer to an other unit or at the end of follow-up
on 30 September 2007. During the analysis, first univariate
Cox proportional hazards models were used with PWV and
OPG levels as predictors to evaluate their separate effects
on cardiovascular mortality (Model A). Next, the analyses
were repeated by including those variables into both models
that showed an association with cardiovascular mortality
in separate univariate models (Model B). The variables
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Table 1. Baseline demographic, clinical, haemodynamic and laboratory
data of the participants (n = 98)
Male n (%) 60 (61)
Age Year 63.4 (14.4)
Dialysis timea Months 29.6 (12.4–48.6)
Residual diuresisa mL/day 600 (100–1300)
Body mass index kg/m2 25.3 (4.5)
Current smoking n (%) 18 (18.4)
Diabetes n (%) 40 (40.8)
Overt cardiovascular disease n (%) 59 (60.2)
Systolic blood pressure MmHg 141.8 (23.8)
Diastolic blood pressure MmHg 77.6 (12.1)
Heart rate n/min 72.8 (13.5)
carotid-femoral PWV m/s 11.2 (3.3)
carotid AI % 23.2 (12.4)
Haemoglobin g/L 113.1 (15.5)
Creatinine µmol/L 677 (243)
Urea mmol/L 20.7 (6.0)
Cholesterol mmol/L 4.5 (1.6)
Triglycerides mmol/L 2.1 (1.5)
HDL-cholesterol mmol/L 1.2 (0.4)
LDL-cholesterol mmol/L 2.6 (0.9)
Sodium mmol/L 137 (2.9)
Potassium mmol/L 5.22 (0.86)
Calcium mmol/L 2.29 (0.21)
Phosphor mmol/L 1.6 (0.54)
Albumin g/L 39.4 (3.99)
Total protein g/L 66.9 (4.71)
PTHa pmol/L 7.0 (4.0–17.5)
25OH vitamin Da µg/L 24.8 (18.9–36.1)
CRPa mg/L 6.8 (4.2–12.4)
OPGa pmol/L 11.1 (7.5–15.9)
Data are mean (SD) or in the case of evidence against normal distribution
(a) median (interquartile range) for continuous variables and n (%) for
categorical variables.
AI: augmentation index; PWV: pulse wave velocity; PTH: parathyroid
hormone; CRP: C-reactive protein; OPG: osteoprotegerin.
considered were the ones listed in Table 1, with the
exception of the carotid augmentation index. Finally, both
PWV and OPG were included into the same adjusted model
(Model C). If OPG and PWV lie along the same pathway
of future morbid cardiovascular events, one expects one or
both variables to lose statistical significance.
Data are presented as mean (standard deviation) or
in the case of evidence against normal distribution as
median (interquartile range) and n (%) for categorical
variables. As serum OPG levels were distributed non-
normally, ln-transformed values were used in the analy-
ses. The SAS statistical package version 6.11 was used
in the analyses. P-values with a two-sided alpha of 0.05
were considered statistically significant. Hazard ratios
(HR) are presented with their 95% confidence intervals in
parentheses.
Results
There were 126 chronic HD patients at the two dialysis
units invited to participate. Of these, 28 patients declined
participation leaving 98 patients for inclusion into the study.
Baseline demographic, medical, laboratory and haemo-
dynamic information of the participants are presented in
Table 1. The most frequent causes for renal disease were
vascular-tubulointerstitial (including hypertension) (39%),
diabetes mellitus (33%) and glomerulonephritis (13%). An-
tihypertensive treatment at baseline included beta-blockers
in 63%, calcium-channel blockers in 62%, angiotensin
receptor blockers or angiotensin-converting enzyme in-
hibitors in 53% and alpha-blockers in 30%. Of our patients
62% were on active vitamin-D therapy and 79% on calcium
carbonate.
PWV measurements were successful in all participants,
with a mean predialysis value of 11.2 m/s (3.3). There were
12 patients with atrial fibrillation. Their PWV (11.7 m/s)
did not significantly differ from a dose with regular rhythm
(11.1 m/s) and the two groups were analysed together.
Results of the univariate and multivariate regression anal-
yses for identifying significant baseline predictors of PWV
are presented in Figure 1 and Table 2. In univariate analysis
we found a strong positive relationship between PWV and
lnOPG (β = 3.09,P< 0.001,R2 = 0.23) (Figure 1). In sepa-
rate univariate models, other significant predictors of base-
line PWV were age, diabetes, history of overt cardiovascu-
lar disease, predialysis systolic blood pressure, predialysis
creatinine, and sodium and CRP levels. The relationship be-
tween PWV and lnOPG remained statistically significant
after adjustment for these covariates (β = 1.48, P = 0.009,
model R2 = 0.54) (Table 2). There was no relationship be-
tween the antihypertensives used and PWV. Furthermore,
parameters of mineral metabolism were not significantly re-
lated to PWV [calcium (P= 0.190), phosphor (P= 0.723),
lnPTH (P = 0.453) and ln25OH vitamin-D (P = 0.791)]
and these were not included in the multivariate linear re-
gression model.
In separate univariate models, using baseline clinical and
laboratorical data as predictors, lnOPG was significantly as-
sociated with age, overt cardiovascular disease, body mass
index, active vitamin-D therapy, and serum triglyceride,
HDL cholesterol and albumin levels. Considering these
variables in a multivariate linear regression model, only age
(β = 0.015, P < 0.001) and BMI (β = −0.026, P = 0.01)
were significantly related to lnOPG (model R2 = 0.432).
During follow-up 35 patients died (mortality rate
20.3/100 patient years) of which 23 were due to cardio-
vascular causes (myocardial infarction: 7, sudden death: 5,
arrhythmia: 2, heart failure: 4, stroke: 5). From the remain-
ing 65 patients 6 were transplanted, 1 stopped dialysis due to
improvement in renal function, 2 were transferred to other
units and data of 54 patients were censored at the end of
follow-up. Kaplan–Meier survival curves for cardiovascu-
lar mortality using tertiles of PWV and OPG are presented
in Figures 2 and 3 (log rankP-values were 0.034 and 0.0006,
respectively). In separate univariate Cox proportional haz-
ard models the following variables were related to cardio-
vascular mortality: PWV [HR = 1.31 (1.14–1.50)], lnOPG
[8.96 (3.07–26.16)], age [1.07 (1.03–1.12)], overt cardio-
vascular disease [3.18 (1.08–9.36)], use of angiotensin-
converting enzyme inhibitor or angiotensin II receptor
blocker [3.60 (1.35–11.65)] and the haemoglobin level
[0.97 (0.95–0.99)]. After adjustment for age, cardiovascu-
lar disease, use of angiotensin-converting enzyme inhibitor
or angiotensin II receptor blocker and the haemoglobin
level in separate multivariate models both PWV and lnOPG
remained significantly related to cardiovascular mortality
(Table 3, Model B). When however both PWV and lnOPG
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Fig. 1. Linear regression between osteoprotegerin levels and carotid-femoral pulse wave velocity.
Table 2. Significant predictors of carotid-femoral pulse wave velocity in univariate and multivariate linear
regression models
Multivariate modela
Univariate models (model R2 = 0.54)
Variables Beta R2 P-value Beta P-value
ln OPG (1 pmol/L) 3.094 0.23 <0.001 1.476 0.009
Age (1 year) 0.119 0.28 <0.001 0.063 0.004
Overt cardiovascular disease 2.738 0.16 <0.001 1.014 0.060
Diabetes mellitus 2.016 0.08 0.002 0.651 0.216
Systolic blood pressure (1 mmHg) 0.045 0.10 0.001 0.042 0.002
lnCRP (1 mg/L) 0.770 0.06 0.010 0.728 0.002
Sodium (1 mmol/L) −0.267 0.05 0.017 −0.134 0.113
Creatinine (100 µmol/L) −0.280 0.03 0.039 −0.014 0.890
aThe multivariate linear regression model considers all variables listed in the table.
were included in the same model only lnOPG remained
a significant predictor of cardiovascular death (Table 3,
Model C).
Discussion
In this study we demonstrated a strong relationship between
PWV and OPG levels and found that the significant pre-
dictive value of PWV for cardiovascular mortality is lost
when OPG levels are also considered in the same model.
These findings may suggest that higher OPG levels and
higher PWV are elements of the same pathway that leads
from arterial calcification to cardiovascular events and that
the mortality risk associated with higher OPG levels may,
in part, be explained by increased PWV.
Arterial calcification is a widespread and progressive ab-
normality in patients on HD that contributes to the high
incidence of cardiovascular events [3]. While the exact
mechanism linking arterial calcification to cardiovascular
events has not been fully evaluated—and it may involve
several separate processes—the positive relationship be-
tween the degree of aortic calcification and PWV provides
one pathway through which arterial calcification can im-
pact on cardiovascular mortality [10]. Indeed, increased
carotid-femoral PWV has repeatedly been shown to be an
independent predictor of cardiovascular mortality in HD
patients [6,7].
Arterial calcification is not a mere consequence of the
disturbance of divalent ion metabolism—frequently seen in
HD patients—but rather, it is an active process regulated
by paracrine and endocrine promoters and inhibitors that
are also central to normal bone formation [11]. Among
these factors is OPG that recently gained clinical attention.
OPG is a glycoprotein that belongs to the tumour necrosis
factor (TNF) receptor superfamily, originally discovered as
an inhibitor of bone resorption. OPG acts as a decoy re-
ceptor of the receptor activator of the nuclear factor κB
ligand (RANKL), which is a strong inducer of osteoclast
differentiation [12]. OPG knockout mice develop osteo-
porosis and widespread arterial calcifications implying that
OPG is also an inhibitor of vascular calcification [19].
OPG is expressed in vascular cells such as coronary smooth
muscle and endothelial cells. Surprisingly, in human cross-
sectional and follow-up studies, higher rather than lower
OPG levels were associated with the degree of coronary and
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Fig. 2. Kaplan–Meier survival curves for cardiovascular mortality in tertiles of carotid-femoral pulse wave velocity.
Fig. 3. Kaplan–Meier survival curves for cardiovascular mortality in tertiles of serum osteoprotegerin levels.
aortic calcification [2,20–23], and in HD patients higher
rather than lower serum OPG levels predicted progression
of aortic calcification [13]. Furthermore, in a recent analy-
sis of non-traditional risk factors, increasing levels of OPG
diminished the association between chronic kidney disease
and coronary calcification, supporting its direct relation-
ship with calcifications [14]. To explain for the apparent
paradox between experimental and human observational
data, it has been suggested that increased OPG levels may
represent an incomplete defence mechanism against factors
that promote atherosclerosis and arterial calcification [22],
or alternatively, higher OPG levels may reflect an ongo-
ing attempt of arterial smooth muscle cells to remodel and
calcify [24]. The first of these two alternatives was also
assumed in postmenopausal osteoporosis, where circulat-
ing OPG levels were higher in women with an increased
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Table 3. Association of carotid-femoral pulse wave velocity (PWV) and
osteoprotegerin (OPG) levels with cardiovascular mortality
Hazard ratio (95% confidence interval)
PWV ln OPG
Model Aa 1.31 (1.14–1.50) 8.96 (3.07–26.16)
Model Bb 1.19 (1.01–1.41) 8.25 (2.22–30.63)
Model Cc 1.11 (0.93–1.33) 7.17 (1.89–27.25)
aSeparate univariate models.
bSeparate models adjusted for age, cardiovascular disease, use of an-
giotensin converting enzyme inhibitor or angiotensin II receptor–blocker
and the haemoglobin level.
cModel containing both PWV and lnOPG and adjusted for age, car-
diovascular disease, use of angiotensin converting enzyme inhibitor or
angiotensin II receptor–blocker and the haemoglobin level.
bone turnover and bone loss. OPG may serve as a protec-
tive mechanism to slow down the increased bone resorption
and subsequent bone loss [25].
While the exact role of OPG in the development and
progression of vascular calcification needs further clarifi-
cation, the clinical relevance of assessing OPG levels was
established by studies demonstrating the predictive value of
higher OPG levels for all cause and cardiovascular mortal-
ity in HD and renal transplant patients [16,17]. Our finding
on the relationship between OPG and PWV provides insight
into downstream elements of the association of OPG with
cardiovascular events. According to our hypothesis a higher
OPG level is a marker of increased arterial calcification and
calcification is related to arterial stiffness; therefore OPG
is expected to be associated with aortic PWV. While several
factors influence arterial stiffness in HD patients such as
older age, increased blood pressure, presence of overt car-
diovascular disease and inflammation, in our multivariate
analysis the relationship between OPG and PWV remained
significant after adjustment for these covariates. This find-
ing is compatible with the above hypothesis.
Two previous studies reported on the analysis of the
association between OPG and PWV. Kim et al. in their
cross-sectional study of newly diagnosed diabetic patients
and controls found a significant correlation between serum
OPG levels and brachial-ankle PWV [26]. More recently,
Stompor et al. reported a significant positive correlation
between serum OPG levels and aortic PWV in patients on
peritoneal dialysis [27]. Our results add to these findings, as
none of the above studies used multivariate analysis to iden-
tify an independent association between OPG and PWV, and
none of them followed the patients in an attempt to eval-
uate the inter-relationship of these parameters on clinical
outcomes.
In the follow-up phase of our study we found that in sep-
arate multivariate survival models both PWV and OPG lev-
els predicted CV mortality, independent of covariates. This
confirms previous studies on the prognostic value of these
parameters in HD patients and provides external validity to
our data. When OPG and PWV were considered in the same
survival model, only OPG remained significantly related to
future cardiovascular death. This result suggests that the
OPG level and PWV provide overlapping prognostic infor-
mation in keeping with our hypothesis that they represent
a common pathway leading to cardiovascular mortality.
Although antihypertensive drug treatment influences ar-
terial stiffness [28], in our study we found no association
between the use of different antihypertensive medications
and PWV. Failure to find such a relationship is likely due
to the cross-sectional nature of our analysis on the determi-
nants of baseline PWV that does not exclude the possibility
of antihypertensives impacting on PWV.
We found no association between parameters of mineral
metabolism and PWV. While abnormalities in these vari-
ables contribute to arterial calcification, their participation
in the development of arterial stiffness in renal patients
has not yet been demonstrated clearly and constantly, with
some studies showing an association [10,29] while others
not [30]. It may be that a snapshot of phosphate or PTH
levels is insufficient to describe the abnormality in mineral
metabolism, particularly if one considers the time needed to
exert an effect on arterial stiffness that may not be apparent
in a cross-sectional analysis.
The use of angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers was related to cardiovascular
mortality in our survival analysis. This surprising finding
is likely explained by the strong correlation between the
presence of cardiovascular disease at baseline and the use
of these drugs (that indicates higher baseline risk in these
patients).
Two of three tertile survival curves in each figure su-
perimpose after 30 months. This is likely explained by the
widening confidence intervals of the survival curves due to
decreasing number of patients at risk by time.
The limitations of our study need to be addressed.
First, our data do not provide an explanation for the
cross-sectional relationship between OPG levels and PWV.
While the known relationship of arterial calcification to
both of these factors could explain our finding, it is to be
acknowledged that in our study we had no direct assessment
of arterial calcification. Alternative explanation for the re-
lationship of OPG with PWV such as the protective effects
of OPG on the endothelial cell survival should also be con-
sidered. Second, the 95% confidence interval for the hazard
ratio of PWV in the survival analysis when both PWV and
OPG were considered (Model C) was wide; therefore we
cannot exclude the possibility that PWV is indeed related
to cardiovascular mortality independent of OPG.
In summary, in this study we found significant positive
relationship between serum OPG levels and aortic PWV in
patients on HD and demonstrated an inter-relationship of
these parameters on their effect on cardiovascular mortality.
These findings are compatible with the hypothesis that the
prognostic significance of high OPG levels is, at least in
part, mediated by higher PWV in these patients. Whether
this relationship is dependent on the degree of aortic cal-
cification and whether the same relationship holds true in
other populations as well need further study.
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